Cargando…
A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
BACKGROUND: Some industrial hygiene studies have assessed occupational exposure to antineoplastic drugs; other epidemiological investigations have detected various toxicological effects in exposure groups labeled with the job title. In no research has the same population been studied both environmen...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074546/ https://www.ncbi.nlm.nih.gov/pubmed/21450074 http://dx.doi.org/10.1186/1471-2458-11-195 |
_version_ | 1782201723848228864 |
---|---|
author | Moretti, Massimo Bonfiglioli, Roberta Feretti, Donatella Pavanello, Sofia Mussi, Francesca Grollino, Maria G Villarini, Milena Barbieri, Anna Ceretti, Elisabetta Carrieri, Mariella Buschini, Annamaria Appolloni, Massimo Dominici, Luca Sabatini, Laura Gelatti, Umberto Bartolucci, Giovanni B Poli, Paola Stronati, Laura Mastrangelo, Giuseppe Monarca, Silvano |
author_facet | Moretti, Massimo Bonfiglioli, Roberta Feretti, Donatella Pavanello, Sofia Mussi, Francesca Grollino, Maria G Villarini, Milena Barbieri, Anna Ceretti, Elisabetta Carrieri, Mariella Buschini, Annamaria Appolloni, Massimo Dominici, Luca Sabatini, Laura Gelatti, Umberto Bartolucci, Giovanni B Poli, Paola Stronati, Laura Mastrangelo, Giuseppe Monarca, Silvano |
author_sort | Moretti, Massimo |
collection | PubMed |
description | BACKGROUND: Some industrial hygiene studies have assessed occupational exposure to antineoplastic drugs; other epidemiological investigations have detected various toxicological effects in exposure groups labeled with the job title. In no research has the same population been studied both environmentally and epidemiologically. The protocol of the epidemiological study presented here uses an integrated environmental and biological monitoring approach. The aim is to assess in hospital nurses preparing and/or administering therapy to cancer patients the current level of occupational exposure to antineoplastic drugs, DNA and chromosome damage as cancer predictive effects, and the association between the two. METHODS/DESIGN: About 80 healthy non-smoking female nurses, who job it is to prepare or handle antineoplastic drugs, and a reference group of about 80 healthy non-smoking female nurses not occupationally exposed to chemicals will be examined simultaneously in a cross-sectional study. All the workers will be recruited from five hospitals in northern and central Italy after their informed consent has been obtained. Evaluation of surface contamination and dermal exposure to antineoplastic drugs will be assessed by determining cyclophosphamide on selected surfaces (wipes) and on the exposed nurses' clothes (pads). The concentration of unmetabolized cyclophosphamide as a biomarker of internal dose will be measured in end-shift urine samples from exposed nurses. Biomarkers of effect and susceptibility will be assessed in exposed and unexposed nurses: urinary concentration of 8-hydroxy-2-deoxyguanosine; DNA damage detected using the single-cell microgel electrophoresis (comet) assay in peripheral white blood cells; micronuclei and chromosome aberrations in peripheral blood lymphocytes. Genetic polymorphisms for enzymes involved in metabolic detoxification (i.e. glutathione S-transferases) will also be analysed. Using standardized questionnaires, occupational exposure will be determined in exposed nurses only, whereas potential confounders (medicine consumption, lifestyle habits, diet and other non-occupational exposures) will be assessed in both groups of hospital workers. Statistical analysis will be performed to ascertain the association between occupational exposure to antineoplastic drugs and biomarkers of DNA and chromosome damage, after taking into account the effects of individual genetic susceptibility, and the presence of confounding exposures. DISCUSSION: The findings of the study will be useful in updating prevention procedures for handling antineoplastic drugs. |
format | Text |
id | pubmed-3074546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30745462011-04-13 A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project Moretti, Massimo Bonfiglioli, Roberta Feretti, Donatella Pavanello, Sofia Mussi, Francesca Grollino, Maria G Villarini, Milena Barbieri, Anna Ceretti, Elisabetta Carrieri, Mariella Buschini, Annamaria Appolloni, Massimo Dominici, Luca Sabatini, Laura Gelatti, Umberto Bartolucci, Giovanni B Poli, Paola Stronati, Laura Mastrangelo, Giuseppe Monarca, Silvano BMC Public Health Study Protocol BACKGROUND: Some industrial hygiene studies have assessed occupational exposure to antineoplastic drugs; other epidemiological investigations have detected various toxicological effects in exposure groups labeled with the job title. In no research has the same population been studied both environmentally and epidemiologically. The protocol of the epidemiological study presented here uses an integrated environmental and biological monitoring approach. The aim is to assess in hospital nurses preparing and/or administering therapy to cancer patients the current level of occupational exposure to antineoplastic drugs, DNA and chromosome damage as cancer predictive effects, and the association between the two. METHODS/DESIGN: About 80 healthy non-smoking female nurses, who job it is to prepare or handle antineoplastic drugs, and a reference group of about 80 healthy non-smoking female nurses not occupationally exposed to chemicals will be examined simultaneously in a cross-sectional study. All the workers will be recruited from five hospitals in northern and central Italy after their informed consent has been obtained. Evaluation of surface contamination and dermal exposure to antineoplastic drugs will be assessed by determining cyclophosphamide on selected surfaces (wipes) and on the exposed nurses' clothes (pads). The concentration of unmetabolized cyclophosphamide as a biomarker of internal dose will be measured in end-shift urine samples from exposed nurses. Biomarkers of effect and susceptibility will be assessed in exposed and unexposed nurses: urinary concentration of 8-hydroxy-2-deoxyguanosine; DNA damage detected using the single-cell microgel electrophoresis (comet) assay in peripheral white blood cells; micronuclei and chromosome aberrations in peripheral blood lymphocytes. Genetic polymorphisms for enzymes involved in metabolic detoxification (i.e. glutathione S-transferases) will also be analysed. Using standardized questionnaires, occupational exposure will be determined in exposed nurses only, whereas potential confounders (medicine consumption, lifestyle habits, diet and other non-occupational exposures) will be assessed in both groups of hospital workers. Statistical analysis will be performed to ascertain the association between occupational exposure to antineoplastic drugs and biomarkers of DNA and chromosome damage, after taking into account the effects of individual genetic susceptibility, and the presence of confounding exposures. DISCUSSION: The findings of the study will be useful in updating prevention procedures for handling antineoplastic drugs. BioMed Central 2011-03-30 /pmc/articles/PMC3074546/ /pubmed/21450074 http://dx.doi.org/10.1186/1471-2458-11-195 Text en Copyright ©2011 Moretti et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Moretti, Massimo Bonfiglioli, Roberta Feretti, Donatella Pavanello, Sofia Mussi, Francesca Grollino, Maria G Villarini, Milena Barbieri, Anna Ceretti, Elisabetta Carrieri, Mariella Buschini, Annamaria Appolloni, Massimo Dominici, Luca Sabatini, Laura Gelatti, Umberto Bartolucci, Giovanni B Poli, Paola Stronati, Laura Mastrangelo, Giuseppe Monarca, Silvano A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project |
title | A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project |
title_full | A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project |
title_fullStr | A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project |
title_full_unstemmed | A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project |
title_short | A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project |
title_sort | study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074546/ https://www.ncbi.nlm.nih.gov/pubmed/21450074 http://dx.doi.org/10.1186/1471-2458-11-195 |
work_keys_str_mv | AT morettimassimo astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT bonfiglioliroberta astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT ferettidonatella astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT pavanellosofia astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT mussifrancesca astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT grollinomariag astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT villarinimilena astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT barbierianna astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT cerettielisabetta astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT carrierimariella astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT buschiniannamaria astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT appollonimassimo astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT dominiciluca astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT sabatinilaura astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT gelattiumberto astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT bartoluccigiovannib astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT polipaola astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT stronatilaura astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT mastrangelogiuseppe astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT monarcasilvano astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT morettimassimo studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT bonfiglioliroberta studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT ferettidonatella studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT pavanellosofia studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT mussifrancesca studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT grollinomariag studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT villarinimilena studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT barbierianna studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT cerettielisabetta studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT carrierimariella studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT buschiniannamaria studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT appollonimassimo studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT dominiciluca studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT sabatinilaura studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT gelattiumberto studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT bartoluccigiovannib studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT polipaola studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT stronatilaura studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT mastrangelogiuseppe studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject AT monarcasilvano studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject |